.
.-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018.
.: "arise: a phase 3 randomized trial of erenumab for episodic migraine."
.
.
but shocking figures uncovered by labour yesterday show some patients are suffering agonising waits of as many as 541 days to begin treatment.
.